top of page



The iFlow uses the traditional subconjunctival fluid drainage pathway. The device however incorporates innovative design features to provide surgeons with a customisable, individualised treatment solution to prevent complications and improve clinical outcomes.

The device is designed to expand the LIQID Medical portfolio to leverage the MIGS glaucoma devices market for patients with earlier stage glaucoma. The device is earmarked for commercialisation readiness in 2023. More details to follow soon...

bottom of page